At a gala ceremony in Los Angeles for the Breakthrough Prize<\/b>\u2014widely known as the “Oscars of Science”\u2014molecular biologist Jean Bennett and ophthalmologist Albert Maguire were honored with a $3 million prize.<\/p>\n
The couple, who met years ago at Harvard Medical School, spent 25 years developing Luxturna<\/b>, the world\u2019s first approved gene therapy for treating inherited blindness. Luxturna is designed for patients with Leber Congenital Amaurosis (LCA)<\/b>, a genetic disorder that leads to total blindness at an early age. The essence of the therapy lies in using a specialized viral vector to deliver a healthy version of the gene into retinal cells, thereby restoring sight. During clinical trials, patients described incredible moments, such as seeing their children’s faces for the first time.<\/p>\n
Notably, during their research, the couple also cured two dogs of blindness; these dogs later became their beloved family pets. At the awards ceremony, Jean Bennett expressed concern over attacks on science and funding cuts by the U.S. administration, which she warned could lead to a “brain drain”<\/b> from the country.<\/p>\n
The same prestigious honor was also awarded to researchers Swee Lay Thein<\/b> and Stuart Orkin<\/b> for their development of gene therapy to treat sickle cell anemia. They discovered that by “switching off” a specific gene (BCL11A<\/b>), they could compel the body to produce the fetal (healthy) form of hemoglobin, effectively curing the disease. This breakthrough laid the foundation for the innovative therapy Casgevy<\/b>, which uses CRISPR<\/b> gene editing to correct a patient\u2019s blood stem cells.<\/p>\n
While these therapies remain complex and expensive for now, scientists agree that we are in a “Golden Age”<\/b> of biomedicine. The future goal is to simplify these technologies to the point where treatment could be as accessible as taking a pill or undergoing direct in vivo gene correction.<\/p>\n